Free Light Chains (FLC)

The next generation Free Light Chain Assay.

About FLC

  • Free Light Chains are immunoglobulin light chains that are circulating in serum in a free state (unbound). Kappa (κ) and Lambda (λ) are the two types of immunoglobulin light chains produced in humans.
  • The quantification of serum FLC is used as an aid in the diagnosis and monitoring of patients with Multiple Myeloma and AL Amyloidosis.
  • A patient’s FLC ratio (kappa FLC/lambda FLC), when compared to a diagnostic reference range, may indicate the presence of certain plasma cell disorders such as Multiple Myeloma and AL Amyloidosis.


Request Information

Key benefits

Superior Clinical Results

17% higher specificity compared to immunoassay, while reducing the impacts of antigen excess and polymerization

Decreased Repeat Rate

Up to 4x fewer repeats compared to immunoassay, saves valuable laboratory resources and lowering the cost of the analysis.

Clinical Performance

Equivalent clinical cut-off criteria (rFLC >100 can be used for diagnosis of MM  and rFLC >20 as SMM progression criterion).

rFLC >100 & rFLC >20
are applicable to the Sebia Assay
rFLC >100 & rFLC >20
are applicable to the Sebia Assay

Main characteristics

Test Principle

Quantification of Kappa or Lambda Free Light Chains is performed with an Enzyme-Linked Immunosorbent Assay (ELISA) procedure utilizing specific antibodies anti-Kappa or anti-Lambda free light chains.

Sample Type

Serum sample

Product details

96 well microplate in strip format.


  • FLC Kappa – P/N: 5102
  • FLC Lambda – P/N: 5103
  • FLC Control Level 1 – P/N: 5112
  • FLC Control Level 2 – P/N: 5113